Compare iShares Bitcoin Trust (IBIT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Medpace Holdings Inc — how do they compare? iShares Bitcoin Trust trades at $46.73 (market cap $67.31B), while Medpace Holdings Inc trades at $614.63 (market cap $16.82B). The key difference: iShares Bitcoin Trust is far larger — about 4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Medpace Holdings Inc for 14 Days on average.
| IBIT | MEDP | |
|---|---|---|
Market Cap | $67.31B | $16.82B |
Volume | 56,154,544 | 223,093 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $630.19 |
52-Week Low | $33.29 | $393.42 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.76, down 0.95% on the day, with technical indicators showing mixed signals. The overall technical outlook is bearish despite moving averages suggesting some bullish momentum. Recent news highlights significant institutional interest with BlackRock's IBIT recording $196 million in daily inflows (24/7 Wall Street, 2026-10-04). The stock faces pressure from oscillators but maintains key support levels at $44-$46.
The outlook remains cautious with institutional inflows providing support, but technical weakness and lack of fundamental data create uncertainty. Investment opportunities exist if technical support holds, while risks include market volatility and dependency on broader Bitcoin ETF trends. Investors should monitor institutional flow data and technical breakouts for directional cues.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
